The present invention relates to products and processes for the treatment or prevention of viral infection(s). In particular the invention relates to the use of one or more proteins, typically obtained from milk, for the treatment or prevention of viral infection(s). In particular embodiments the invention uses combinations of milk proteins for the treatment or prevention of viral infection(s). The products of the invention may be used in combination with other active agents, including other antiviral agents.

The present invention is directed to a bacterial, preferably probiotic bacterial peptidoglycan hydrolase (PGH), a peptidoglycan hydrolase (PGH)-comprising bacterial, preferably probiotic bacterial strain or a peptidoglycan hydrolase (PGH)-comprising composition for use in the therapeutic or prophylactic treatment of a bacterial infection, preferably for the treatment of a bacterial infection resulting in diarrhea. Further aspects of the present invention relate to corresponding methods for preparing a medicament and to a corresponding method of treatment.

The present invention relates to mannanase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.

Provided are an animal cell strain for use in producing a glycoprotein which uses a high-mannose sugar chain as a main N-glycan structure, a method for use in producing a glycoprotein by using the cell strain, a glycoprotein produced by using the method, and a use thereof. At least two genes from among a Golgi mannosidase and an endoplasmic reticulum mannosidase gene of the cell strain are damaged or knocked out.

The present disclosure relates to compositions and methods useful for the production of recombinant glycoproteins in filamentous fungal cells, such as Trichoderma cells, wherein at least 90% (mol %), preferably at least 95% of the total neutral N-glycans of said produced recombinant glycoprotein are mammalian-like N-glycans. More specifically, the invention provides a filamentous fungal cell comprising i. one or more mutations that reduces or eliminates one or more endogenous protease activity compared to a parental filamentous fungal cell which does not have said mutation(s); ii. a polynucleotide encoding a heterologous catalytic subunit of oligosaccharyl transferase; iii. a recombinant polynucleotide for increasing 1, 2 mannosidase activity;and, iv. a recombinant polynucleotide encoding said heterologous glycoprotein.

Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.

The present invention is directed to a bacterial, preferably probiotic bacterial peptidoglycan hydrolase (PGH), a peptidoglycan hydrolase (PGH)-including bacterial, preferably probiotic bacterial strain or a peptidoglycan hydrolase (PGH)-including composition for use in the therapeutic or prophylactic treatment of a bacterial infection, preferably for the treatment of a bacterial infection resulting in diarrhea. Further aspects of the present invention relate to corresponding methods for preparing a medicament and to a corresponding method of treatment.

Described herein are methods and genetically engineered fungal cells useful for producing target molecules containing mammalian-like complex N-glycans or containing intermediates in a mammalian glycosylation pathway.

Provided are methods and compositions for treating an individual with cancer by administering to the individual a composition that includes a Dectin-2 stimulating agent that stimulates Dectin-2 signaling in myeloid cells (e.g., induces Dectin-2 clustering on the cell surface), thereby stimulating an anti-cancer immune response in the individual. In some cases, the myeloid cells are tumor-associated myeloid (TAM) cells. Methods and compositions are also provided for: treating an individual with cancer via contacting a cancer cell from the individual with an alpha-mannosidase class 1 inhibitor (e.g., to increase the display and/or density of terminal mannose/mannobiose residues on the surface of target cells) in vitro or ex vivo and introducing the contacted cancer cell into the individual; stimulating an antigen presenting cell (APC) via contacting a cancer cell with an alpha-mannosidase class 1 inhibitor and contacting the APC with the inhibitor-contacted cancer cell; and stimulating an APC via contacting it with a subject Dectin-2 stimulating agent.

Provided are compositions and methods for inhibiting transmission of viruses that use mosquitoes as vectors, such as dengue (DENV), Zika (ZIKV) and Chikungunya (CHIKV) viruses. Inhibiting transmission includes reducing viral load of the virus in mosquitoes. The viral load is reduced in mosquitoes that are exposed to the virus by introducing into the mosquitoes or mosquito larvae one or more agents that can participate in RNA interference (RNAi) of expression of one or more mosquito genes, such as alpha-mannosidase 2, or Cadherin87A, or a combination thereof. Also provided are modified mosquitoes or mosquito larvae that comprise the RNAi agents. The modified mosquitoes can be released into a population of unmodified mosquitoes to inhibit transmission of the virus between mammalian hosts. Also provided are compositions comprising an RNAi agent or an expression vector that encodes the RNAi agent for use in the described methods.